Galapagos (GLPG) announced that the FDA has granted RMAT designation to GLPG5101, a second generation anti-CD19/4-1BB CAR-T product candidate for the treatment of relapsed/refractory mantle cell lymphoma.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GLPG:
- Deutsche Bank downgrades Galapagos to Sell amid ‘too much uncertainty’
- Galapagos downgraded to Sell from Hold at Deutsche Bank
- Galapagos Hold Rating: Navigating Management Changes and Strategic Uncertainties
- Galapagos NV Reports 2025 Half-Year Results and Strategic Updates
- Galapagos NV Reports Strong H1 2025 Results Amid Strategic Transformation